{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:33:42Z","timestamp":1790724822888,"version":"4.1.0"},"reference-count":25,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["eo.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aim to investigate the time toxicity of patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate in a single institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This is a retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate at the Alexander Fleming Institute were included. Our primary endpoint was to evaluate time toxicity, which accounted for every day that the patient had contact with any department of any healthcare institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our cohort included 21 patients with metastatic disease, female sex 86%, and a median age of 55 (IQR 44\u201363). The primary tumour site was the small intestine in 47.6% of the cases. The median number of previous systemic treatments for advanced disease was two (IQR 2\u20133). The overall response rate was 19%, and 66.6% had clinical benefit. The median calculated \u2018time toxicity\u2019 was 11 days (IQR 8\u201318), representing 5.7% of the total treatment duration. The main contributors to time toxicity included infusion days, blood draws, radiological scans, and hospitalisations (median of 4 days for each).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lutetium-177 Dotatate treatment for gastroenteropancreatic neuroendocrine tumours was associated with low time toxicity, excellent tolerability, a good response and prolonged PFS, of which the median was not reached in the short follow-up we present. Newer treatments with different mechanisms of action provide longer survival and widen the landscape of choices. Understanding new clinical endpoints is important for the transition into a more modern clinical practice, strengthening personalised and patient-oriented strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-24-0028","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T07:30:52Z","timestamp":1728891052000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":1,"title":["Time toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours"],"prefix":"10.1530","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4740-1060","authenticated-orcid":true,"given":"Marcos Daniel","family":"Bortz","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Romina Luca","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Waisberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Enrico","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Freile","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Catani","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Esteso","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Chac\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-5466","authenticated-orcid":true,"given":"Juan Manuel","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina","family":"Racioppi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Alexander Fleming Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"European Journal of Nuclear Medicine and Molecular Imaging","first-page":"800","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","unstructured":"Bodei LMueller-Brand JBaum RPPavel MEH\u00f6rsch DO\u2019Dorisio MSO\u2019Dorisio TMHowe JRCremonesi MKwekkeboom DJ, et al. 2013 The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 40 800\u2013816. (https:\/\/doi.org\/10.1007\/s00259-012-2330-6)"},{"key":"bib2","series-title":"Clinical Cancer Research","first-page":"4617","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","unstructured":"Brabander Tvan der Zwan WATeunissen JJMKam BLRFeelders RAde Herder WWvan Eijck CHJFranssen GJHKrenning EP & Kwekkeboom DJ 2017 Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clinical Cancer Research 23 4617\u20134624. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743)"},{"key":"bib3","series-title":"Scandinavian Cardiovascular Journal","first-page":"4","article-title":"Patient-prioritized primary endpoints in clinical trials","volume":"56","author":"Bundgaard","year":"2022","unstructured":"Bundgaard JSIversen K & Bundgaard H 2022 Patient-prioritized primary endpoints in clinical trials. Scandinavian Cardiovascular Journal 56 4\u20135. (https:\/\/doi.org\/10.1080\/14017431.2022.2035808)"},{"issue":"Supplement79","key":"bib4","series-title":"Value in Health","article-title":"PDB9 real world comparison of healthcare resource use of 177lutetium oxodotretotide (LUTATHERA\u00ae) in England and matched cohort analysis of progressive neuroendocrine tumour patients using the hospital episodes statistics database","volume":"24","author":"Cox","year":"2021","unstructured":"Cox TO\u2019Connell MLeeuwenkamp OPalimaka S & Reed N 2021 PDB9 real world comparison of healthcare resource use of 177lutetium oxodotretotide (LUTATHERA\u00ae) in England and matched cohort analysis of progressive neuroendocrine tumour patients using the hospital episodes statistics database. Value in Health 24(Supplement79) . (https:\/\/doi.org\/10.1016\/j.jval.2021.04.407)"},{"key":"bib5","series-title":"Journal of Gastrointestinal Oncology","first-page":"103","article-title":"Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience","volume":"10","author":"Foubert","year":"2019","unstructured":"Foubert FSalimon MDumars CRegenet NGirot PVenara ASenellart HHeymann MFMatysiak-Budnik T & Touchefeu Y 2019 Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. Journal of Gastrointestinal Oncology 10 103\u2013111. (https:\/\/doi.org\/10.21037\/jgo.2018.09.13)"},{"key":"bib6","series-title":"JAMA Oncology","first-page":"1757","article-title":"Has the current oncology value paradigm forgotten patients\u2019 time?: too little of a good thing","volume":"7","author":"Fundytus","year":"2021","unstructured":"Fundytus APrasad V & Booth CM 2021 Has the current oncology value paradigm forgotten patients\u2019 time?: too little of a good thing. JAMA Oncology 7 1757\u20131758. (https:\/\/doi.org\/10.1001\/jamaoncol.2021.3600)"},{"key":"bib7","series-title":"Oncology","first-page":"370","article-title":"Decision making criteria in oncology","volume":"98","author":"Glatzer","year":"2018","unstructured":"Glatzer MPanje CMSir\u00e9n CCihoric N & Putora PM 2018 Decision making criteria in oncology. Oncology 98 370\u2013378. (https:\/\/doi.org\/10.1159\/000492272)"},{"key":"bib8","series-title":"Journal of Clinical Oncology","first-page":"1611","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022a","unstructured":"Gupta AEisenhauer EA & Booth CM 2022a The time toxicity of cancer treatment. Journal of Clinical Oncology 40 1611\u20131615. (https:\/\/doi.org\/10.1200\/JCO.21.02810)"},{"key":"bib9","series-title":"JCO Oncology Practice","first-page":"245","article-title":"Time-related burdens of cancer care","volume":"18","author":"Gupta","year":"2022b","unstructured":"Gupta AJensen EHVirnig BA & Beg MS 2022b Time-related burdens of cancer care. JCO Oncology Practice 18 245\u2013246. (https:\/\/doi.org\/10.1200\/OP.21.00662)"},{"key":"bib10","series-title":"JCO Oncology Practice","first-page":"302","article-title":"Opportunity costs of surgical resection and perioperative chemotherapy for locoregional pancreatic adenocarcinoma","volume":"18","author":"Lim","year":"2022","unstructured":"Lim SAHao SBBoyd BAMitsakos AIrish WBurke AMParikh AA & Snyder RA 2022 Opportunity costs of surgical resection and perioperative chemotherapy for locoregional pancreatic adenocarcinoma. JCO Oncology Practice 18 302\u2013309. (https:\/\/doi.org\/10.1200\/OP.21.00311)"},{"key":"bib11","series-title":"Cancer Management and Research","first-page":"5629","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","unstructured":"Man DWu JShen Z & Zhu X 2018 Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Management and Research 10 5629\u20135638. (https:\/\/doi.org\/10.2147\/CMAR.S174907)"},{"key":"bib12","series-title":"Contemporary Clinical Trials Communications","first-page":"100486","article-title":"Choosing primary endpoints for clinical trials of health care interventions","volume":"16","author":"McLeod","year":"2019","unstructured":"McLeod CNorman RLitton ESaville BRWebb S & Snelling TL 2019 Choosing primary endpoints for clinical trials of health care interventions. Contemporary Clinical Trials Communications 16 100486. (https:\/\/doi.org\/10.1016\/j.conctc.2019.100486)"},{"key":"bib13","series-title":"Journal of Oncology Practice","first-page":"499","article-title":"Value-based calculators in cancer: current state and challenges","volume":"13","author":"Nabhan","year":"2017","unstructured":"Nabhan C & Feinberg BA 2017 Value-based calculators in cancer: current state and challenges. Journal of Oncology Practice 13 499\u2013506. (https:\/\/doi.org\/10.1200\/JOP.2017.022947)"},{"key":"bib14","series-title":"Annals of Oncology","first-page":"844","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","unstructured":"Pavel M\u00d6berg KFalconi MKrenning EPSundin APerren ABerruti A & ESMO Guidelines Committee 2020 Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 31 844\u2013860. (https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304)"},{"key":"bib15","series-title":"New England Journal of Medicine","first-page":"501","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","unstructured":"Raymond EDahan LRaoul JLBang YJBorbath ILombard-Bohas CValle JMetrakos PSmith DVinik A, et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501\u2013513. (https:\/\/doi.org\/10.1056\/NEJMoa1003825)"},{"key":"bib16","series-title":"Acta M\u00e9dica Portuguesa","first-page":"726","article-title":"Tratamento de Tumores Neuroend\u00f3crinos Gastroenteropancre\u00e1ticos com 177Lu-DOTA-TATE: experi\u00eancia do Instituto Portugu\u00eas de Oncologia do Porto","volume":"29","author":"Sampaio","year":"2016","unstructured":"Sampaio ILLuiz HVViolante LSSantos APAntunes LTorres ISanches CAzevedo I & Duarte H 2016 Tratamento de Tumores Neuroend\u00f3crinos Gastroenteropancre\u00e1ticos com 177Lu-DOTA-TATE: experi\u00eancia do Instituto Portugu\u00eas de Oncologia do Porto. Acta M\u00e9dica Portuguesa 29 726\u2013733. (https:\/\/doi.org\/10.20344\/amp.7306)"},{"key":"bib17","series-title":"Journal of Clinical Oncology","first-page":"2925","article-title":"Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","unstructured":"Schnipper LEDavidson NEWollins DSBlayney DWDicker APGanz PAHoverman JRLangdon RLyman GHMeropol NJ, et al. 2016 Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. Journal of Clinical Oncology 34 2925\u20132934. (https:\/\/doi.org\/10.1200\/JCO.2016.68.2518)"},{"key":"bib18","series-title":"Journal of the National Comprehensive Cancer Network","first-page":"839","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","unstructured":"Shah MHGoldner WSBenson ABIIIBergsland EBlaszkowsky LSBrock PChan JDas SDickson PVFanta P, et al. 2021 Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 19 839\u2013868.(https:\/\/doi.org\/10.6004\/jnccn.2021.0032)"},{"key":"bib19","series-title":"American Society of Clinical Oncology Educational Book","first-page":"e389516","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh","year":"2023","unstructured":"Shickh SLeventakos KLewis MABombard Y & Montori VM 2023 Shared decision making in the care of patients with cancer. American Society of Clinical Oncology Educational Book 43 e389516. (https:\/\/doi.org\/10.1200\/EDBK_389516)"},{"key":"bib20","series-title":"BMC Cancer","first-page":"10","article-title":"Lutetium oxodotreotide (177 Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland","volume":"21","author":"Smith-Palmer","year":"2021","unstructured":"Smith-Palmer JLeeuwenkamp ORVirk J & Reed N 2021 Lutetium oxodotreotide (177 Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer 21 10. (https:\/\/doi.org\/10.1186\/s12885-020-07710-7)"},{"key":"bib21","series-title":"European Journal of Nuclear Medicine and Molecular Imaging","first-page":"2037","article-title":"[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective","volume":"49","author":"Spada","year":"2022","unstructured":"Spada FCampana DLamberti GLaudicella RDellamano RDellamano LLeeuwenkamp O & Baldari S 2022 [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. European Journal of Nuclear Medicine and Molecular Imaging 49 2037\u20132048. (https:\/\/doi.org\/10.1007\/s00259-021-05656-x)"},{"key":"bib22","series-title":"New England Journal of Medicine","first-page":"125","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","unstructured":"Strosberg JEl-Haddad GWolin EHendifar AYao JChasen BMittra EKunz PLKulke MHJacene H, et al. 2017 Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine 376 125\u2013135. (https:\/\/doi.org\/10.1056\/NEJMoa1607427)"},{"key":"bib23","series-title":"Journal of Clinical Oncology","first-page":"3063","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","unstructured":"Yao JCHassan MPhan ADagohoy CLeary CMares JEAbdalla EKFleming JBVauthey J-NRashid A, et al. 2008 One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063\u20133072. (https:\/\/doi.org\/10.1200\/JCO.2007.15.4377)"},{"key":"bib24","series-title":"Journal of Clinical Oncology","first-page":"3906","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016a","unstructured":"Yao JCPavel MLombard-Bohas CVan Cutsem EVoi MBrandt UHe WChen DCapdevila Jde Vries EGE, et al. 2016a Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. Journal of Clinical Oncology 34 3906\u20133913. (https:\/\/doi.org\/10.1200\/JCO.2016.68.0702)"},{"key":"bib25","series-title":"Lancet","first-page":"968","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016b","unstructured":"Yao JCFazio NSingh SBuzzoni RCarnaghi CWolin ETomasek JRaderer MLahner HVoi M, et al. 2016b Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387 968\u2013977. (https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X)"}],"container-title":["Endocrine Oncology"],"original-title":[],"link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/4\/1\/EO-24-0028.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/4\/1\/EO-24-0028.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/4\/1\/EO-24-0028.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:50:32Z","timestamp":1784555432000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/eo\/article\/1566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":25,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eo-24-0028","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}